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Atrial fibrillation (AF) is the most common cardiac dys-
rhythmia encountered by cardiac surgeons in their practice. 
The incidence of AF rises with age from approximately 0.1% 
in adults younger than 55 to 9% in individuals older than 
80. The routine performance of detailed examinations be-
fore cardiac surgery entails that, in most cases, AF patients 
are receiving treatment; however, there are still patients 
who remain undiagnosed and unaware of the disease due 
to the lack of symptoms [1–3].
Atrial fibrillation is associated with a manifold increase 
in the risk of ischemic stroke. It also significantly increases 
the incidence of serious conditions, such as congestive heart 
failure, premature death, or thromboembolic complications. 
Therefore, we should all strive to treat AF in our patients and 
prevent the occurrence of associated complications [4, 5].
The most common treatment for AF patients which can 
be employed by any physician is currently oral anticoagu-
lation (OAC). The principles of OAC use in AF patients are 
discussed in detail in recommendations issued by scientific 
associations.
The guidelines of the European Society of Cardiology 
(ESC) recommend that all patients diagnosed with AF should 
be assessed with regard to the risk of thromboembolic 
complications using the CHA2DS2-VASc scale; patients with 
scores of 1 or more should undergo effective stroke preven-
tion, mostly in the form of OAC, which necessitates the evalu-
ation of its effectiveness and safety with regard to the risk of 
hemorrhagic complications. A relatively precise assessment 
of this risk can be accomplished by using the HAS-BLED scale.
Considering the numerous possible contraindications 
for OAC, medication intolerance, and potential complica-
tions during OAC, this type of prevention cannot be suc-
cessfully employed in all AF patients, as the risk of compli-
cations often exceeds the potential benefits of OAC.
Physicians have always searched for new treatments for 
their patients, including those in whom the current thera-
pies are unsuccessful or cannot be used for various rea-
sons. One of the methods for safeguarding patients from 
complications caused by AF, including ischemic stroke, 
has led to the strategy of performing left atrial appendage 
(LAA) occlusion.
The LAA occlusion (LAAO) has been associated with 
cardiac surgery procedures from its very inception. Initially, 
the procedures consisted in suturing the LAA during mitral 
commissurotomy, later also during mitral valve plasty and 
replacement.
In accordance with the currently binding guidelines, LAAO 
should be considered in all patients at high risk of hemor-
rhagic complications with HAS-BLED scores of 3 or more.
The latest ESC guidelines also recommend performing 
LAAO in patients with high risk of stroke and contraindi-
cations for OAC; surgical LAAO can also be considered in-
traoperatively in all patients undergoing any cardiac proce-
dures [6–8].
Initially, cardiac surgeons performed LAAO with regular 
lung staplers, loops, or sutures; however, some of the clini-
cal studies analyzing such procedures have proved that the 
effectiveness of this type of management is very low, and 
LAA occurs very often. Some researchers state outright that 
these methods are completely ineffective and offer only 
a false sense of security.
The conducted meta-analyses show that the results of 
nearly all older surgical LAAO methods are unequivocal to 
say the least.
The most effective current surgical procedure for 
achieving LAAO is to cut off the LAA and suture the stump 
using a regular surgical suture.
The LAA amputation was a part of surgical left atrial ab-
lation proposed by Dr James Cox. The results showed that, 
after 10 years, as many as 99% of patients did not suffer 
from ischemic stroke. Unfortunately, we do not know to 
what extent these good results can be attributed to LAAO 
in comparison to the restoration of sinus rhythm.
A number of questions related to all the currently used 
surgical LAAO procedures are expected to be answered by 
the recently started multicenter Left Atrial Appendage Oc-
clusion Study III (LAAOS III). The enrollment is ongoing, and 
it is hoped that the outcomes will result in the formulation 
of recommendations important for our community.
The only fully effective surgical LAAO system is the Atri-
Clip, based on a metal clip placed over the LAA [9]. It is 
very easy to use and guarantees very good results, which 
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has made it the most popular medical product for surgical 
LAAO. In Poland, good results with this system have been 
achieved by Prof. Suwalski’s center in Warsaw, Prof. Zem-
bala’s Silesian center, and Prof. Kapelak’s center in Krakow.
Technological progress associated with the development 
of percutaneous methods has enabled the performance of 
some myocardial revascularization procedures without the 
need to open the chest. Percutaneous techniques have also 
recently begun to be used in endocardial LAAO procedures.
Devices dedicated for LAAO (such as WATCHMAN, AM-
PLATZER Cardiac Plug, and LARIAT), introduced through 
a catheter into the LAA or used externally, enable the safe 
exclusion of the LAA from the circulation and are widely 
used, including in Poland.
The first device for percutaneous LAAO was the PLAATO 
system. Despite its great commercial success, it has been 
discontinued and is no longer available.
Another device for LAAO is the Amplatzer Cardiac Plug 
(ACP). Its significant advantage is that, after being properly 
placed in the LAA, its disc completely seals off the interior 
of the LAA.
The Watchman device, like the ACP and PLAATO, is made 
of a nitinol mesh. It is currently the best studied system for 
LAAO, and a great number of clinical studies and registries 
prove its efficacy. The prospective randomized multicenter 
study PROTECT AF analyzed the device, providing reliable 
results and conclusions. The study proved that the efficacy 
of the Watchman device in preventing stroke is at least as 
high as warfarin therapy, whereas the associated risk of 
hemorrhagic complications is significantly lower.
This conclusion was groundbreaking for all those in-
volved in LAAO procedures, as it proved that LAAO can be 
a valuable alternative to OAC in the prevention of ischemic 
stroke in AF patients with contraindications for OAC.
The present-day knowledge on the results of using the 
ACP and Watchman implants in humans is quite extensive 
and very well documented. Registry studies analyzing all 
systems based on LAAO implants are ongoing, and, hope-
fully, they will provide results that will enable a precise 
evaluation of the efficacy of these devices.
It remains puzzling why the manufacturers of both im-
plant-based systems recommend postoperative OAC after 
LAAO also in patients with contraindications for OAC. The 
reason is likely to be related to effective healing and im-
plant coverage, but can this justify exposing the patient to 
the risk of hemorrhagic episodes? It should also be noted 
that long-term complications from the use of endocardial 
implants (which include both the ACP and the Watchman 
devices) remain unknown.
Subsequent generations of percutaneous implant-based 
systems should significantly reduce the number of compli-
cations and improve the safety of implantation. One should 
keep in mind, however, that the long-term influence of en-
docardial implants on human health is yet to be studied.
Time will tell whether the future will bring a mass re-
call of endocardial implants, as is the case with endocardial 
electrodes, which were supposed to be absolutely safe.
Experiences gathered from surgical and percutaneous 
LAAO systems and thoracoscopic left atrial ablation as well 
as cooperation between researchers from the University of 
California and the company SentreHeart Inc. have enabled 
the development of the novel LARIAT system. The system 
has the advantages of implant-based systems, but with-
out their drawbacks and limitations. It also draws on the 
advantages of surgical systems without inheriting their 
limitations in the form of postoperative recanalization or 
the need for opening the chest. Its use is completely percu-
taneous [10, 11].
The LARIAT system is not a nitinol implant like the 
abovementioned ACP and Watchman devices, but rather 
it uses a simple loop from a traditional insoluble surgical 
suture. The loop is placed on the LAA externally and is very 
effective in excluding the LAA from blood circulation.
The system was initially used in vitro in order to en-
sure its proper functioning; the many subsequent tests in 
animal models demonstrated its safety and efficacy. The 
results of these studies were published in prestigious jour-
nals including Circulation: Cardiovascular Interventions and 
Heart Rhythm. Our center actively participated in these 
studies and experiments [12, 13].
The first use of the LARIAT system in a human subject 
took place at the Clinic of Cardiac and Vascular Surgery 
and Transplantology of the John Paul II Specialist Hospital 
in Cracow. Appropriate institutions including the Central 
Register of Clinical Trials (CEBK, Centralna Ewidencja Badań 
Klinicznych) and the Bioethics Committee of the Jagiellonian 
University approved the procedure, which took place in No-
vember 2009. The surgical team including Bartuś, Sadowski, 
and Kapelak performed the first procedure and several sub-
sequent clinical trials, which unequivocally confirmed the 
safety and effectiveness of the analyzed LARIAT system [10].
The most important reports documenting the results of 
trials in human subjects are those published in the Journal 
of the American College of Cardiology (JACC), Heart Rhythm, 
and Circulation: Arrhythmia and Electrophysiology [10, 11, 
14]; the author of the present paper was the first author 
of these articles and performed all the LAAO procedures on 
which the articles were based. The clinical studies and mul-
ticenter registries that we participated in resulted in obtain-
ing the CE marking for the product and, subsequently, the 
approval of the Food and Drug Administration for its use in 
human subjects both in the USA and the European Union.
The LARIAT device is manufactured in one size and is 
suitable for almost any anatomical conditions, in contrast 
to all other implant-based systems, which require the 
production of several model sizes and precise preopera-
tive measurements. This universality of the LARIAT system 
greatly facilitates the performance of the implantation pro-
cedure.
However, its most important and unique characteristic 
in comparison with all the other percutaneous LAAO sys-
tems is the fact that no OAC is required.
As there is no implant, and the suture is not in contact 
with the patient’s blood, the only thing remaining in the 
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blood flow is the patient’s own tissue, which is already cov-
ered with live endothelium.
This is obviously of paramount importance for patients 
with contraindications for OAC, who no longer have to be 
exposed to the risk of hemorrhagic complications.
Furthermore, this allows the prevention of all complica-
tions normally associated with OAC.
The lack of an endocardial implant eliminates the risk 
of complications related to the presence of a foreign body 
within the heart (including implant migration, emboliza-
tion, and coagulation), which is unfortunately associated 
with all implant-based systems.
The effectiveness of the LARIAT system ranges from 
96% to 100%, which is comparable with other LAAO sys-
tems. The rate of complications associated with the peri-
cardial access after the use of the LARIAT system are report-
ed by various centers around the world at 3–5%; the rate 
of complications associated with the LARIAT device itself is 
reported at 0%.
Our center in Krakow was able to significantly reduce 
the number of all complications thanks to extensive experi-
ence in performing these procedures. At present, our com-
plication rate is approximately 1%; this includes patients 
with various severe concomitant diseases.
At this point, it is worth commenting on the individual 
publications from American centers which report higher 
rates of complications. In the opinion of the author of this 
article and many other specialists, the higher number of 
complications reported by these centers can be attributed 
to the limited experience of the operators and erroneous 
qualification of patients for LAAO.
The use of other pericardial access techniques (tele-
scopic needle) and anti-inflammatory agents during the 
postoperative course significantly limits both short- and 
long-term complications, as proven by a study encompass-
ing several hundred patients undergoing this procedure in 
the USA [15, 16].
Our most recent experiences also demonstrate that the 
LARIAT system is the only percutaneous device for LAAO 
which offers not only mechanical, but also electric isolation 
of the LAA. The results of these procedures were published 
in Heart Rhythm and Circulation: Arrhythmia and Electro-
physiology [13, 14].
The electrical isolation of the LAA provided by the LARIAT 
system has been demonstrated in these publications, which 
may be very important in the case of patients with AF trig-
gers within the LAA.
The performance of LAAO using the LARIAT system can 
simultaneously remove the cause of AF in these patients. 
Our experience includes several AF patients who never 
again suffered from an AF episode after being treated with 
LAAO using the LARIAT loop. Therefore, it appears that sys-
tems employing epicardial access and based on the well-
known and safe surgical suture, such as the LARIAT system, 
are fundamentally better. This stems from their capability 
of providing complete mechanical isolation from the cir-
culating blood and electrical isolation of the LAA without 
the use of extracorporeal circulation or the need to leave 
an implant within the heart. Many authors believe that 
implant-based methods will always be less attractive for 
the patient, as the presence of an endocardial implant and 
its contact with the blood current will always be associated 
with the risk of potential complications [17–20].
The LARIAT system has been successfully deployed in 
nearly 5000 patients in over 180 centers around the world. 
Since 2009, I have performed over 400 procedures using 
the LARIAT loop, which is the largest number of such proce-
dures in the world.
I would like to encourage the readers to monitor the 
literature associated with LAAO and to attempt to perform 
these procedures on their own. 
The efforts of our society (the Polish Society of Cardio-
thoracic Surgeons), especially Prof. Zembala, Prof. Marusze-
wski, and Prof. Różański, have resulted in the possibility of 
obtaining a certificate attesting to the skills required for 
LAAO. This is certainly a milestone that will enable cardi-
ac surgeons to independently perform and account for all 
LAAO procedures.
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